Nicholas Hornstein, Gastrointestinal Medical Oncologist at Northwell Health, shared a post on LinkedIn:
“NICHE-2 absolutely delivers. Game over for chemo in dMMR colon cancer
In locally advanced dMMR colon cancer, FOxTROT already showed us chemo doesn’t work, and now NICHE-2 makes it undeniable.
Neoadjuvant nivolumab + ipilimumab
- 99% pathologic response
- 67% pathologic CR
- Zero recurrences to date at 3 years
This is the final coffin nail for perioperative chemotherapy in this setting. ATOMIC is already on life support despite being published less than a year ago.
The real question now: with Cercek’s rectal data, can we safely omit surgery next? At minimum, this should be the new standard. At maximum, it’s the start of a paradigm shift.”
More posts featuring Nicholas Hornstein.